https://www.cariboubio.com/
Caribou Biosciences | Developing Sophisticated Allogeneic Cell Therapies
Caribou is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for devastating human diseases.
caribou biosciencesdevelopingsophisticatedallogeneiccell
https://www.globenewswire.com/news-release/2024/09/25/2952993/0/en/Caribou-Biosciences-to-Present-Preclinical-Data-Supporting-Development-of-CB-010-for-Lupus-at-the-American-College-of-Rheumatology-Convergence-2024.html
Caribou Biosciences to Present Preclinical Data Supporting
BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing...
caribou biosciencespreclinical datapresentsupporting
https://www.benzinga.com/quote/CRBU/analyst-ratings
Caribou Biosciences Analyst Ratings and Price Targets | NASDAQ:CRBU | Benzinga
Explore Caribou Biosciences analyst ratings and price targets (NASDAQ:CRBU) on Benzinga. Stay updated on expert opinions and forecasts for CRBU stock.
caribou biosciencesanalyst ratingsprice targetsnasdaqcrbu
https://www.benzinga.com/news/earnings/22/08/28427414/recap-caribou-biosciences-q2-earnings
Recap: Caribou Biosciences Q2 Earnings - Caribou Biosciences (NASDAQ:CRBU) - Benzinga
Aug 9, 2022 - Caribou Biosciences (NASDAQ:CRBU) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the...
caribou biosciencesrecapearningsnasdaqcrbu
https://www.businesswire.com/news/home/20210722006072/en/Caribou-Biosciences-Announces-Pricing-of-Upsized-Initial-Public-Offering
Caribou Biosciences Announces Pricing of Upsized Initial Public Offering
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the pricing of its upsized initial publi...
caribou biosciencesannouncespricinginitialpublic